Table 2: Summary of studies conducted on human and animal showing potent anti-inflammatory effect of curcumin as well as its nontoxic effect on human and animals [91-95].

Scientist Conducted Study Part of Curcuma Longa Plant Used Study Conducted on
Study Conducted on Human Trial
Models Type of Study Conclusion Inference
Sample size
Ashish Shubhas et al.(2013) [91] Curcuminoids and oil free aqueous extract of C. longa
Albino swiss Mice and Albino Wistar rats NA NA Xylene induced ear edema and cotton pallet granuloma model Comparative. COFAE at dose level (p< 0.05) reduce inflammation in each animal model. On comparative study the oil free aqueous extract showed better anti-inflammatory effect as compared to curcuminoids. The active constituents of curcumin has potent anti-inflammatory effect in its different forms.
Chang et al.
(2001) [92]
8000 mg curcumin
Per day
NA 25 subjects Phase I NA NA The study showed that curcumin is not toxic to humans when administered for 3 months up to the dose of 8,000 mg/day (orally). Curcumin is nontoxic to human.
Satoskar et al.(1986) [93] Curcumin (1200 mg/d) and phenylbutazone (300mg/d) NA 45 subjects NA NA Comparative
Controlled trail.
Controlled trial study was conducted
(5-days) with
45 postsurgical patients divided into groups
placebo, curcumin (1200 mg/d), and
phenylbutazone (300 mg/d). Phenylbutazone and curcumin showed better anti-inflammatory effect.
Curcumin showed better anti-inflammatory effect.
Bundy Rafe et al. (2004) [94] 1 tablet of curcumin extract per 8th day NA 500 IBS
207 subjects
(screened for study)
Phase II NA Partially blinded, randomized, two-dose, pilot study. The prevalence rate of inflammatory bowel syndrome found to be declined up to 41% and 57% and further the percentage declined to 53%-60% between base line after treatment in both groups. The anti-inflammatory effect of curcumin has been seen in inflammatory bowel syndrome.
Chandran Binu et al.
(2012) [95]
Curcumin (500 mg) and Diclofenac Sodium (50 mg) NA 45 Phase II NA Randomized, single-blinded, pilot study. Patients were randomly allocated in 1:1:1 ratio for administration of curcumin 500 mg (Group I) or curcumin 500 mg + diclofenac sodium 50 mg (Group II), or diclofenac sodium 50 mg (Group III) over a period of 8 weeks. Curcumin showed better anti-inflammatory effect and reduced pain also.